Immunic (NASDAQ:IMUX) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Immunic (NASDAQ:IMUX) from a sell rating to a hold rating in a research report released on Friday.

Separately, Brookline Capital Management reiterated a buy rating and set a $10.00 price target on shares of Immunic in a research report on Friday, April 5th.

Immunic Stock Performance

Immunic stock opened at $1.18 on Friday. Immunic has a 12-month low of $0.95 and a 12-month high of $3.11. The company has a 50-day moving average price of $1.33 and a 200 day moving average price of $1.27.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.03. On average, equities research analysts expect that Immunic will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Immunic by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 1,691,000 shares of the company’s stock valued at $2,536,000 after purchasing an additional 28,411 shares during the period. Sierra Summit Advisors LLC purchased a new position in shares of Immunic in the fourth quarter valued at approximately $487,000. Northern Trust Corp boosted its stake in shares of Immunic by 49.2% in the fourth quarter. Northern Trust Corp now owns 164,439 shares of the company’s stock valued at $247,000 after purchasing an additional 54,225 shares during the period. Gratus Capital LLC boosted its stake in shares of Immunic by 15.1% in the fourth quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock valued at $2,912,000 after purchasing an additional 254,999 shares during the period. Finally, Sweet Financial Partners LLC purchased a new position in shares of Immunic in the fourth quarter valued at approximately $45,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.